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Background: Senile plaques consisting of amyloid-beta (Aβ) are the major pathological hallmark of Alzheimer’s
disease (AD) and have been the primary therapeutic target. Immunotherapies, which are designed to remove brain
Aβ deposits, increased levels of soluble Aβ and accelerated brain atrophy in some clinical trials, suggesting that the
solubilization of Aβ deposition might facilitate the formation of more toxic Aβ oligomers and enhance
neurotoxicity.
Methods: The capacity of antibodies against different epitopes of Aβ to disaggregate preformed Aβ fibrils was
investigated. The co-incubation of antibodies and Aβ fibrils was then tested for neurotoxicity both in vitro and
in vivo.
Results: After the incubation of preformed Aβ fibrils with the N-terminal antibody 6E10, the fibrils were decreased,
while the oligomers, mostly dimers and trimers, were significantly increased. However, no such effects were observed
for antibodies targeting the middle domain (4G8) and C-terminus of Aβ (8G7). The co-incubates of preformed Aβ fibrils
with 6E10 were more neurotoxic, both in vitro and in vivo, than the co-incubates with 4G8 and 8G7.
Conclusions: Our results indicate that the antibody targeting the N-terminus of Aβ promoted the transformation of
Aβ from fibrils into oligomers and increased neurotoxicity. Immunotherapies should take into consideration the
enhanced neurotoxicity associated with the solubilization of Aβ deposits by antibodies against the Nterminus of Aβ.
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Senile plaque containing amyloid-beta (Aβ) protein are a
major hallmark of Alzheimer’s disease (AD) and have been
considered as an important therapeutic target of AD [1, 2].
Immunotherapies are promising for the treatment of AD
by removing senile plaques and attenuating the pathologies
secondary to Aβ, such as tau pathologies, neuroinflamma-
tion, dendritic dysfunction and neuronal loss [3]. However,
current clinical trials of immunotherapies for AD failed to* Correspondence: yanjiang_wang@tmmu.edu.cn
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article, unless otherwise stated.improve cognition and reverse disease progression. Several
significant adverse effects were observed in AD clinical tri-
als, including meningoencephalitis, vasogenic oedema and
microhaemorrhage [4]. Some immunotherapies could not
reduce or even increased the levels of soluble Aβ in both
animal and clinical trials [5, 6]. It was suggested that oligo-
mers are the most toxic form of Aβ aggregates [7]. In this
regard, the transformation of Aβ oligomers into fibrils
might be an adaptive change in AD; disaggregation Aβ fi-
brils into oligomers in immunotherapies may enhance the
neurotoxicity of this peptide. This might explain the failure
of AN1792 clinical trials in which alleviation of the brain
amyloid burden was accompanied by accelerated brain at-
rophy and the deterioration of cognitive function indistributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
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aimed to investigate the capacity of antibodies targeting dif-
ferent epitopes of Aβ to disaggregate preformed Aβ fibrils
and to determine whether antibody-induced disaggregation
of Aβ fibrils can facilitate the formation of oligomers and
enhance the neurotoxicity of Aβ.
Materials and methods
Preparation of Aβ fibrils
Synthetic Aβ42 was purchased from American Peptide
(CA, USA). Aβ fibrils were prepared according to previ-
ous protocols [9]. Briefly, Aβ1–42 was dissolved in
100 μL of ice-cold Dulbecco’s modified Eagle’s medium
(DMEM, Gibco) (pH = 7.5) containing 0.05 % NaN3.
Solutions containing 10 μg of Aβ42 were incubated at
37 °C for 72 h for polymerization. The reaction tubes
were not agitated during the reaction. After incubation,
the mixture was centrifuged at 4 °C for 20 min at
8000×g. The supernatant was discarded, and the precipita-
tion was resuspended in 50 μL of phosphate-buffered sa-
line (PBS) containing 0.05 % NaN3 in an Eppendorf tube
and stored at 4 °C for further use.
Preparation of antibody-Aβ co-incubates
The monoclonal antibodies used in the present study,
including 6E10 (antigen epitope, Aβ residues 1–17; af-
finity to Aβ monomer, 22.3 nM [10]; Covance), 4G8
(antigen epitope, Aβ residues 17–24; affinity to Aβ
monomer, 30.1 nM [10]; Covance) and 8G7 (antigen
epitope, Aβ residues 41–42; Acris), were dissolved in
distilled water at a concentration of 1 μg/μL. Preformed
Aβ fibrils generated from 10 μg of Aβ42 were resus-
pended in 9 μL of distilled water, followed by the
addition of 1 μL of antibody solution. Aβ fibril suspen-
sions with 1 μL PBS were incubated under the same
conditions as a control. The mixture was incubated at
37 °C for 72 h before the assay.
Thioflavin T assay
To test whether antibodies, including 6E10, 4G8 and
8G7, can disaggregate Aβ fibrils, Aβ42 (10 μM) was dis-
solved in distilled water and incubated in 96-well plates
at 37 °C for 48 h for fibrillization. Antibodies (2 μg in
1 μL) were then added to the wells, and the samples
were incubated at 37 °C for another 72 h. Aβ42 mono-
mers were incubated with PBS under the same condi-
tions as the negative control. The samples were then
measured by adding 5 μM thioflavin T (ThT) solution
(50 mM phosphate buffer, pH 6.0). Fluorescence inten-
sity was monitored at an excitation wavelength of
450 nm and an emission wavelength of 482 nm by a
spectrometer (Synergy H4, Bio Tek). Each experiment
was performed in triplicate, and the means of the tripli-
cates were used for the statistical analysis.Western blot
A 10-μL aliquot of the co-incubation samples as described
above was loaded onto SDS-PAGE gradient (4 %-10 %-
16 % acrylamide) gels. Separated Aβs were transferred to
nitrocellulose membranes. The blots were probed with
biotin-conjugated 6E10. Infrared dye-conjugated streptavi-
din (Li-COR Biosci, NE) was used to detect positive bands.
The membranes were visualized with an Odyssey Imaging
System (Odyssey V3.0). The density was calculated with
western blot analysis software (Quantity One V4.62).
Transmission electron microscopy negative staining
To validate the effect of antibodies on the disaggregation
of Aβ fibrils, transmission electron microscopy (TEM)
negative staining was performed. A 10-μL aliquot of
preformed Aβ42 fibrils that were co-incubated with
antibodies (as prepared above) was spotted onto a
glow-discharged, carbon-coated Formvar grid and incu-
bated for 20 min at room temperature. The droplet
then was displaced with an equal volume of 2.5 % (v/v)
glutaraldehyde and incubated for an additional 6 min.
Finally, the peptide was stained with 2 % aqueous phos-
photungstic acid for 30 s. Samples were examined using
a Joel 1200 EX transmission electron microscope equipped
with a Megaview 3 digital camera. The area of fibrils was
selected for automatic quantification using Image J soft-
ware, and the analysis yielded the fractional area of the total
positive staining against the area of the analysed field.Annexin V labelling
An annexin V staining kit (KeyGEN BioTECH) was used
according to the manufacturer’s instructions to evaluate
the proportion of apoptotic cells. Briefly, SH-SY5Y cells
were seeded at a density of 105 cells/mL in 12-well plates
(Sarstedt) in DMEM (Gibco) containing 10 % foetal bo-
vine serum (FBS, Gibco) at 200 μL per well. The co-
incubates (20 μL) of different antibodies or PBS were
added to the wells. After 3 h of incubation, live cells
were washed three times with warm PBS for 5 min.
Then, they were treated with FITC-labelled annexin V
for 5 min at room temperature and subsequently washed
with PBS. The cells were then incubated with DAPI
(1:1000) for 5 min at room temperature and washed
with PBS. Cell images were collected with a B50 fluores-
cence microscope.
MTT assays
The neurotoxicity of the co-incubation samples was mea-
sured using an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide) viability assay as previously
described [11]. Briefly, SH-SY5Y cells were seeded at a
density of 105 cells/mL in a 96-well plate in DMEM con-
taining 10 % FBS at 50 μL per well. The co-incubates
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10 μL of MTT (Sigma-Aldrich, USA, 5 mg/mL in PBS)
was added to each well, and the samples were incubated
for 4 h. A solubilization solution (10 % SDS in 0.01 M
hydrochloric acid) was added to dissolve the insoluble
purple formazan product to produce a coloured solution.
Each assay was performed in triplicate. The optical density
(OD) was read at 600 nm on a multi-well scanning spec-
trophotometer (BIO-RAD Model 2550 EIA Reader).
Neurite outgrowth assay
For the neurite outgrowth assays, SH-SY5Y cells were
cultured for 7 days in a medium with 1 % FBS and
10 μM all-trans-retinoic acid (RA) (Sigma, USA) and
then incubated with 2 μL of the co-incubates for 24 h.
Each assay was performed in triplicate. The cell images
were taken by microscopy, and the length of 10 neurites
per view field were measured. Data from 20 view fields
per group were analysed.
Mouse and brain injections of antibody-Aβ co-incubates
Six-month-old C57BL/6J mice were housed and main-
tained in the animal facility at Daping Hospital. We
used only females in our analyses (n = 5 for each anti-
body group). A midsagittal incision was made to expose
the cranium, and a burr hole was drilled with a dental
drill over the left hemisphere to the following coordi-
nates: anteroposterior, −0.2 mm; lateral, 1 mm; and
ventral, 2.2 mm, which were all taken from the bregma.
Co-incubates (5 μL) were injected into the lateral ven-
tricle of the mice. PBS (5 μL) was injected in the same
manner as a control. Forty-eight hours after injection,
the brains were fixed and sectioned. Five sections
around the injection site were selected per animal. This
study and all experimental protocols were approved,
and the methods were carried out in accordance with
the guidelines of the Animal Care Committee of the
Third Military Medical University (TMMU).
Analysis of neuronal apoptosis
To detect apoptotic cells, terminal deoxynucleotidyl
transferase dUTP nick end labelling (TUNEL) staining
and immunofluorescence with anti-activated caspase-3
were used. For TUNEL staining, apoptotic cells were la-
belled using an in situ Death Detection Kit, POD
(Roche), according to the manufacturer’s instructions. The
sections were also detected with NeuN and caspase-3
double-labelling immunofluorescence. The area of the
hippocampus was selected for automatic quantification
using Image J software to detect NeuN and caspase-3
positive neurons, yielding the area fraction of the total
positive staining against the area of analysed tissue. The
average of the individual measurements was used to
calculate group means and standard error of mean(SEM). The quantification of the area fraction and posi-
tive cells was performed using ImageJ.
Statistical analysis
The results were presented as the mean ± SEM. The
data were first assessed for normal distribution by the
one-sample Kolmogorov-Smirnov test. Statistical com-
parisons among groups were tested using one-way
ANOVA. Two-way ANOVA was used to compare the
antibody-induced time-dependent disaggregation of Aβ
fibrils in the ThT assay. P values <0.05 were considered
statistically significant.
Results
Antibody targeting the N-terminus of Aβ promoted the
disaggregation of preformed Aβ fibrils
TEM and ThT assays were conducted to investigate the
capacity of antibodies to disaggregate preformed Aβ fi-
brils. After the incubation of preformed Aβ fibrils with
N-terminal antibody 6E10, which targets amino acids
1–16 of Aβ, truncated fibrils and small aggregates of a
variable size were observed in the TEM assay (Fig. 1a).
However, after the incubation with 4G8, which targets
amino acids 17–24 of Aβ, and 8G7, which targets the
C-terminus of Aβ and PBS-treated samples, highly ag-
gregated fibrils were observed under TEM. This vari-
ance in the disaggregation ability of the antibodies was
indicated by significantly lower area fractions of Aβ fi-
brils in the 6E10 group (P = 0.001 vs PBS) (Fig. 1b).
The ThT assay was conducted to further investigate
the time-dependent disaggregation of Aβ fibrils induced
by antibodies. Aβ42 monomers were aggregated for
48 h and then co-incubated with antibodies for an add-
itional 72 h for disaggregation. We found that the fluor-
escence intensity induced by Aβ fibrils was significantly
lower in 6E10-treated samples compared to 4G8- and
8G7-treated samples and the PBS controls (Fig. 1c).
These data suggest that an antibody against the N-
terminus of Aβ was able to disaggregate Aβ fibrils.
Antibody targeting the N-terminus of Aβ promoted the
transformation of Aβ fibrils to oligomers
We next used western blot to detect whether disaggre-
gation of Aβ fibrils could facilitate the formation of Aβ
oligomers. After the incubation of preformed Aβ fibrils
with antibodies, the co-incubates were subjected to
western blotting. We found that more dimers and tri-
mers (P < 0.001 vs PBS) and fewer fibrils (P = 0.001 vs
PBS) and aggregates with a molecular weight more than
30 kDa (P = 0.016 vs PBS) were observed in the 6E10-
treated samples compared with the 4G8- and 8G7-
treated samples (Fig. 1d, e). There was no difference in
the amount of Aβ oligomers among the 4G8/8G7-
treated samples and PBS controls. These findings
Fig. 1 An N-terminal antibody promotes the disaggregation of preformed Aβ fibrils. a Representative TEM images of Aβ fibrils after treatment
with antibodies targeting different sequences of Aβ. b Quantification of the fibrillar area fractions of TEM images. **P < 0.01 vs PBS. c Fluorescence
intensity of the ThT assays showing the capacity of antibodies to disaggregate preformed Aβ fibrils. Aβ42 monomers were aggregated for 48 h
and were then incubated with antibodies or PBS for an additional 72 h for disaggregation. **P < 0.01. d Western blot image showing the capacity
of antibodies to disaggregate preformed Aβ fibrils. e Quantification of the relative intensity of western blot bands. **P < 0.01 vs control, #P < 0.05
and ##P < 0.01 vs PBS. TEM transmission electron microscopy, ThT thioflavin T
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facilitated the transformation of Aβ fibrils into Aβ
oligomers.
Antibody targeting the N-terminus of Aβ increased the
neurotoxicity of Aβ in vitro
Based on the above findings, we proposed that the disag-
gregation of preformed fibrils might increase the toxicity
of Aβ by facilitating the formation of Aβ oligomers.
Annexin V staining, neurite outgrowth and MTT assayswere conducted to investigate the neurotoxicities of
antibody-fibril co-incubates in vitro. Interestingly, the N-
terminal antibody 6E10 significantly increased the neuro-
toxicity of Aβ fibrils as reflected by the significant increase
in the percentage of annexin V-labelled cells (Fig. 2a, b),
the decrease in cell viability (Fig. 2c) and the neurite
length (Fig. 2d, e) of SH-SY5Y cells. However, the percent-
age of annexin V-labelled cells, cell viability and neurite
length were comparable among the 4G8, 8G7 and PBS
groups (Fig. 2a–c).
Fig. 2 Disaggregation of preformed Aβ fibrils by an N-terminal antibody increases the neurotoxicity of Aβ in vitro. a Representative images of annexin
V staining in SH-SY5Y cells treated with the co-incubates of antibodies and Aβ. The neurons were counterstained with DAPI. Scale bar = 100 μm.
b Quantification of the percentages of annexin V-labelled neurons. c MTT assays showing the cell viability of SH-SY5Y cells. d Representative images of
SH-SY5Y cells treated with co-incubates of antibodies and Aβ. e Quantification of the neurite length of SH-SY5Y cells. **P < 0.01 vs control, ##P < 0.01
vs PBS
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neurotoxicity of Aβ in vivo
We further investigated the neurotoxicity of Aβ fibril-
antibody co-incubates in vivo. After the injection of co-
incubates into the lateral ventricle of 6-month-old C57
mice in each group, we conducted NeuN and caspase-3
double staining, as well as TUNEL staining, to investi-
gate the neurotoxicity in vivo. Consistent with the
in vitro results, co-incubates in the 6E10 group signifi-
cantly induced neuronal apoptosis in both the CA3 re-
gion (P < 0.001 vs PBS; P < 0.001 vs control) (Fig. 3a, b)
and the dendrite gyrus (P < 0.001 vs PBS; P < 0.001 vs
control) (Fig. 3c, d). However, no significant difference
was found in neuronal apoptosis among the 4G8, 8G7
and PBS groups (Fig. 3a–d).
Discussion
In the present study, for the first time, we found that an
antibody against the N-terminus of Aβ, but not anti-
bodies against the middle domain or the C-terminus of
Aβ, disaggregated preformed Aβ fibrils, leading to theformation of oligomers and enhancing the neurotoxicity
of Aβ both in vitro and in vivo.
Immunotherapies are promising for the treatment of
AD by reducing amyloid deposition and improving cog-
nition in animal models of AD. The mechanisms of the
antibody-mediated Aβ clearance included solubilization
of Aβ fibrils [12, 13], antibody-mediated phagocytosis of
Aβ by microglia [14, 15] and sequestration of Aβ in the
blood as a peripheral “sink” [16]. However, despite their
effects in reducing brain Aβ deposition, immunother-
apies have not been successful in improving cognition in
clinical trials [17–20]. Although these failures are mainly
attributed to the fact that interventions occurred too late
to reverse the disease, the adverse effects associated
with immunotherapies including autoimmune meningo-
encephalitis, vasogenic oedema and microhaemorrhage
are also important factors that compromise the thera-
peutic efficacy of immunotherapy [4]. An important
phenomenon derived from previous clinical and experi-
mental studies is that immunotherapies are effective in
reducing brain amyloid deposition but cannot reduce
Fig. 3 (See legend on next page.)
Liu et al. Journal of Neuroinflammation  (2015) 12:153 Page 6 of 8
(See figure on previous page.)
Fig. 3 Disaggregation of preformed Aβ fibrils by an N-terminal antibody increases the neurotoxicity of Aβ in vivo. a Neuronal apoptosis in the
CA3 region was visualized using NeuN and activated caspase-3 co-staining (scale bar = 50 μm). b Quantification of apoptosis by activated caspase-3 in
the CA3 region. c Neuronal apoptosis in the dendrite gyrus was visualized using TUNEL staining (scale bar = 200 μm). d Quantification of apoptotic
cells in the dendrite gyrus that were stained by TUNEL (n = 5 per group, mean ± SEM, One-way Anova,*P < 0.05 and **P < 0.01 vs control, #P < 0.05 and
##P < 0.01 vs PBS)
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6, 21]. The increase in soluble Aβ is a result of the
solubilization of Aβ fibrils by antibodies. Convincing
data has arisen suggesting that the soluble oligomeric
Aβ species are the primary toxic agents in AD [7].
Whether transformation of deposited Aβ plaques into
soluble Aβ can favour the formation of Aβ oligomers re-
mains unknown. We have previously proposed that
solubilization of Aβ deposits might favour the formation
of more toxic Aβ oligomers, thus enhancing the neuro-
toxicity of Aβ in immunotherapies; we have termed
this phenomenon as the “dust-raising effect” [4]. In the
present study, we found that an antibody against the N-
terminus of Aβ (6E10) promoted the transformation of
Aβ fibrils into toxic oligomers, primarily Aβ dimers and
trimers, which are the major toxic forms of Aβ [22, 23]
that cause significant neuronal death in the brain of
mice. This finding is of significant clinical relevance. In
the AN1792 trial, brain Aβ deposition was removed;
however, the soluble Aβ species were elevated, and brain
volume loss was accelerated [24]. The reason for this
dissociation between Aβ clearance and brain atrophy re-
mains unclear. It was proposed that the volume changes
were due to amyloid removal and associated cerebral
fluid shifts [24]. According to our present findings, it is
likely that the oligomeric Aβ species derived from the
solubilization of Aβ deposits caused further damage to
neurons in the brain, leading to the subsequent acceler-
ation of brain volume loss.
In addition, the adverse effects of immunotherapies were
also associated with the epitopes of the Aβ N-terminus.
Vasogenic oedema and microhaemorrhage were observed
in passive immunotherapies utilizing antibodies against the
N-terminus of Aβ [17] but not antibodies against the mid-
dle domain of Aβ [18]. The possible reason for this is that
antibodies bind to the N-terminus of Aβ, which is exposed
on the surface of Aβ fibrils, and form immune complexes
that induce subsequent inflammatory reactions [4, 25]. We
also found that antibodies to the N-terminus of Aβ can
promote the generation of Aβ by cross-reacting with neu-
rons via the N-terminal epitope of Aβ, which is located in
the extracellular domain of APP and is exposed on the sur-
face of neurons [26, 27].
In our present study, we found that an antibody tar-
geting the N-terminus of Aβ, but not antibodies to the
middle domain and C-terminus of Aβ, was able to disag-
gregate Aβ fibrils, suggesting that the therapeuticfunction of anti-Aβ antibodies are closely related to their
antigen epitopes. Conformational analysis showed that
the N-terminus of Aβ was exposed on the surface, but
the middle domain and C-terminus were embedded in
the core of Aβ fibrils [28]. Thus, N-terminal antibodies
can potently clear Aβ plaque because they are accessible
to Aβ fibrils, but antibodies to the middle domain and C-
terminus of Aβ may have limited potential to recognize
preformed Aβ fibrils and are therefore less effective as a
treatment to remove Aβ deposits. This notion was sup-
ported by the fact that solanezumab, an antibody against
the middle domain of Aβ, is not as effective in reducing
the brain Aβ burden [18] compared to bapineuzumab, an
antibody against the N-terminus of Aβ that is able to re-
move brain Aβ deposits, as evidenced by recent immuno-
therapeutic clinical trial [17, 29]. It was revealed that
antibodies targeting the middle domain of Aβ have a
better anti-aggregation capacity than those targeting
the N-terminus [30]. The competency of these anti-
bodies in antagonizing Aβ aggregation can be explained
by the findings that the middle domain of Aβ is key for
Aβ aggregation [31]. In this regard, antibodies against
the middle domain of Aβ might be more effective as a
preventative treatment before the deposition of Aβ.
In conclusion, the present study indicated that
solubilization of Aβ fibrils by an antibody against the
N-terminus of Aβ leads to the formation of more toxic
Aβ oligomeric species. The therapeutic and adverse
effects of anti-Aβ antibodies are associated with their
antigen epitopes. This should be taken into consider-
ation for the efficacy and safety of immunotherapies in
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